Table 2.
Impact of CVVH treatment on whole group
| Treatment | ||||
|---|---|---|---|---|
| CVVH n = 75 | no CVVH n = 55 | p value | ||
| Demographics | Age, years | 44.7 ± 13.9 | 51.5 ± 16.6 | NS |
| Male, n (%) | 65 (86.7%) | 31 (56.4%) | ||
| Time from the first symptoms to hospitalization, median hours (IQR) | 16 (26.8 to 3.8) | 19.5 (48 to 11.5) | NS | |
| APACHE II at admission, points | 7.8 ± 4.1 | 7.5 ± 4.8 | NS | |
| IAP on admission, mmHg | 14.2 ± 4.0 | 11.8 ± 3.0 | 0.048 | |
| SOFA on admission, points | 2.4 ± 2.2 | 2.2 ± 1.9 | NS | |
| Necrotizing SAP, n (%) | 62 (82.7%) | 28 (50.9%) | <0.001 | |
| MODS, n (%) | 70 (93.3%) | 53 (96.3%) | NS | |
| Organ dysfunctions | Renal dysfunction, n (%) | 32 (42.7%) | 15 (27.3%) | NS |
| Pulmonary dysfunction, n (%) | 12 (16.0%) | 5 (9.1%) | NS | |
| Liver dysfunction, n (%) | 12 (16.0%) | 6 (10.9%) | NS | |
| Cardiovascular, n (%) | 6 (8%) | 3 (5.5%) | NS | |
| Hematologic, n (%) | 5 (6.7%) | 4 (7.2%) | NS | |
| Neurologic, n (%) | 15 (20%) | 6 (10.9%) | NS | |
| Complications | Metabolic acidosis, n (%) | 24 (32%) | 7 (12.7%) | 0.013 |
| Pleural effusion, n (%) | 47 (62.7%) | 14 (25.5%) | <0.001 | |
| Pneumonia, n (%) | 31 (41.3%) | 5 (9.1%) | <0.001 | |
| Atelectasis, n (%) | 11 (14.7%) | 2 (3.6%) | 0.043 | |
| Pancreatic/peripancreatic infection, n (%) | 21 (28%) | 16 (29.1%) | NS | |
| Surgical intervention, n (%) | 21 (28%) | 15 (27.3%) | NS | |